Reata’s Bardoxolone Shot Down, But US FDA Advisors Offer Suggestions For Improved Study
Executive Summary
Advisory committee unanimously votes against bardoxolone for Alport syndrome, unconvinced drug slows progression of chronic kidney disease and concerned about safety signals suggesting it could make the disease worse. However, panel offers Reata suggestions for a better-designed trial.
You may also be interested in...
Reata, Kyowa Kirin End Bardoxolone CKD Development
Reata was expecting positive results from a Phase III study by Japanese licensee for diabetic kidney disease after a US rejection for Alport Syndrome last year, but the US company and Asia partner Kyowa Kirin have now decided to end development in CKD indications after a missed secondary endpoint seen as critical to approval in Japan.
Reata Puts Hopes On Partner Study To Support Bardoxolone Resubmission
Reata says partner Kyowa Kirin’s outcomes study of bardoxolone in chronic kidney disease may address the questions cited by the FDA in its complete response letter for Alport syndrome.
Keeping Track: Jardiance Approved Across Heart Failure Spectrum, But US FDA Turns Down Bardoxolone, Terlipressin
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.